Sign in
4

Changes in Ownership

Kalaris Therapeutics, Inc. Filed Acc 0000899243-22-025233

Chief Commercial Officer sold 515 shares at $3.63 ($1,871)

  • Chief Commercial Officer acquired 14,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

VAN BEEK JEROEN B · Chief Commercial Officer

Table I: Non-derivative

2 lines
Date Transaction Shares Price Value Owned after D/I
2022-06-03 Sale : show line 1 in the form −515 $3.63 $1,871 389,011 D
2022-07-01 Grant or award : show line 2 in the form +14,000 403,011 D
Open-market sales · 515 sh · avg $3.63 · $1,871

Table II: Derivative

1 line
Date Transaction Shares Exercise Expires Underlying Owned after D/I
2022-07-01 Grant or award : show line 3 in the form Stock Option (Right to Buy) +26,000 $4.13 2032-07-01 26,000 26,000 D
Loading xslF345X03/doc4.xml…